Concert Pharmaceuticals to Report First Quarter 2018 Financial Results on May 3, 2018, & Present at Upcoming Investor Confere...
April 26 2018 - 7:00AM
Business Wire
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced
that it will report its first quarter 2018 financial results on
Thursday, May 3, 2018, before the U.S. financial markets open. The
Company will host a conference call and webcast at 8:30 a.m. ET to
discuss first quarter financial results and provide a business
update. Individuals interested in participating in the call should
dial (855) 354-1855 (U.S. and Canada) or (484) 365-2865
(International).
In addition, the Company today announced that it will
participate at the following upcoming investor conferences:
- The 43rd Annual Deutsche Bank
Securities Healthcare Conference on May 8, 2018 at 8:00 a.m. ET in
Boston, MA;
- The UBS Global Healthcare Conference on
May 22, 2018 at 10:30 a.m. ET in New York, NY;
- The Jefferies 2018 Global Healthcare
Conference on June 6, 2018 at 2:00 p.m. ET in New York, NY;
and
- The JMP Securities Life Sciences
Conference on June 20, 2018 at 9:30 a.m. ET in New York, NY.
A live webcast of the first quarter financial results and the
investor presentations may be accessed in the Investors section of
the Company’s website at www.concertpharma.com. Please log on to
the Concert website approximately 15 minutes prior to the scheduled
webcast to ensure adequate time for any software downloads that may
be required. A replay of the first quarter financial results
webcast will be available on Concert’s website for three months. A
replay of the investor conference webcasts will be available on
Concert’s website for two weeks following the presentations.
About Concert
Concert Pharmaceuticals is a clinical stage biopharmaceutical
company focused on applying its DCE Platform® (deuterated chemical
entity platform) to create novel medicines designed to address
unmet patient needs. The Company’s approach starts with starts with
previously studied compounds, including approved drugs, in which
deuterium substitution has the potential to enhance clinical
safety, tolerability or efficacy. Concert has a broad
pipeline of innovative medicines targeting autoimmune and
inflammatory diseases and central nervous systems (CNS) disorders.
For more information please visit www.concertpharma.com or follow
us on Twitter at @ConcertPharma or on LinkedIn.
Concert Pharmaceuticals Inc., the CoNCERT
Pharmaceuticals Inc. logo and DCE Platform are registered
trademarks of Concert Pharmaceuticals, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180426005071/en/
Concert PharmaceuticalsJustine Koenigsberg,
781-674-5284ir@concertpharma.com
Concert Pharmaceuticals (NASDAQ:CNCE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Concert Pharmaceuticals (NASDAQ:CNCE)
Historical Stock Chart
From Apr 2023 to Apr 2024